What technical signals does GYRODYNE (GYRO) have?

GYRODYNE current technical signals: no active technical signal.

Is GYRODYNE a cup-and-handle pattern?

No. GYRODYNE has no valid cup-and-handle signal right now.

What are GYRODYNE's financials and valuation?

GYRODYNE's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

GYRODYNE

GYRO · Nasdaq

$5.00+1.01%

2026-09-04 close

GYRODYNE last closed at $5.00 (+1.01%) on 2026-09-04. Listed on Nasdaq; price, financials and dividends update daily after market close.

Loading chart…

No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions

277 picks

Next-day win rate

44.2%

Avg next-day

-0.28%

vs market

-0.51%p

Every new-high-plus-volume pick we actually published (US market) — not this stock alone.

Trade plan

EntryAccount sizeStopTarget (optional)Risk per trade (%)

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

PER — · PBR 0.36 — own-history percentile —/100 · 92/100

Open self-history band

PER—/100

PBR92/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Financial safety

Reference indicatorAs of 2024

Grey zoneFinancial-metric reference signal

Altman Z'' zoneZ'' 1.23

Distress

Grey

Safe

The marker shows the current Z'' value within the displayed zones.

Altman Z'': 1.23
Beneish M-Score: —
Sloan accrual: —

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

2/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score2/9

Profitability

Positive ROANot passed
Positive OCFNot passed
Improving ΔROANot passed
Accruals (OCF > net income)Not passed

Leverage & liquidity

Lower debtPass
Higher current ratioNot passed
No new sharesPass

Efficiency

Higher gross marginNot passed
Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Connections

AI-extracted related companies · for reference

Competitors

United TherapeuticsPrice comovement r=0.06 (1 year)Bristol-Myers SquibbPrice comovement r=0.14 (1 year)Johnson & JohnsonPrice comovement r=0.01 (1 year)Merck & Co.Price comovement r=0.04 (1 year)Gilead SciencesPrice comovement r=0.16 (1 year)PfizerPrice comovement r=0.07 (1 year)

Same theme

Kezar Life SciencesPliant TherapeuticsPrice comovement r=0.11 (1 year)Sarepta TherapeuticsPrice comovement r=0.15 (1 year)Alexion Pharmaceuticals

🔗 See in the full market map →

Recent filings

Filings for overseas stocks are on the way. For now we cover Korean stocks only.

About GYRODYNE

What technical signals does GYRODYNE (GYRO) have?: GYRODYNE current technical signals: no active technical signal.
Is GYRODYNE a cup-and-handle pattern?: No. GYRODYNE has no valid cup-and-handle signal right now.
What are GYRODYNE's financials and valuation?: GYRODYNE's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy